What is the appropriate action if a patient exhibits signs of bleeding while receiving thrombolytics?

When a patient exhibits signs of bleeding while receiving thrombolytics, the appropriate action is to stop the infusion and notify the medical doctor (MD). Thrombolytics are powerful medications that dissolve blood clots, but they can also increase the risk of bleeding significantly. Immediate action is required to mitigate potential complications.

Stopping the infusion halts the administration of the thrombolytic agent, thereby minimizing further risk of exacerbating the bleeding. Notifying the MD is crucial as they can assess the situation and decide on further interventions, which may include providing supportive care or deciding on the necessity of administering reversal agents if applicable. This collaborative approach ensures patient safety and aligns with protocols for managing complications associated with thrombolytic therapy.

Continuing the infusion while merely monitoring could lead to worsening of the patient's condition, while increasing the dosage or administering additional medication would likely compound the risk of bleeding and is contrary to established medical guidelines for managing adverse effects from thrombolytics.